Your email has been successfully added to our mailing list.

×
0.0181382614647502 0.0181382614647502 0.0181382614647502 0.0181382614647502 0.0102669404517455 0.0184804928131418 0.0188227241615333 0.026694045174538
Stock impact report

BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
Company Research Source: Seeking Alpha
Revenue for the three months ended March 31, 2024, were $211.1 million, as compared to $1.8 million for the same period in the prior year. The $209.3 million net increase for the three months ended March 31, 2024, compared to the same period in the prior year, was primarily due to the recognition of non-refundable upfront payments under the Bayer and the Kyowa Kirin exclusive license agreements. Recommended For You More Trending News Recommended For You More Trending News About BBIO Stock Related Stocks Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
KNBWY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
KNBWY alerts

from News Quantified
Opt-in for
KNBWY alerts

from News Quantified